<DOC>
	<DOC>NCT02186652</DOC>
	<brief_summary>Multicenter, comparative single-dose pharmacokinetic (PK) study</brief_summary>
	<brief_title>PK Study With Pantoprazole in Obese Children and Adolescents</brief_title>
	<detailed_description>Evaluate the pharmacokinetics of pantoprazole in obese children and adolescents with gastroesophageal reflux disease (GERD) following administration of an oral dose of pantoprazole.</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>1. Participant is between 6 and 17 (inclusive) years of age at the time of consent 2. BMI ≥95th percentile 3. Diagnosis of GERD established prior to 7 days before receipt of study drug dose defined as 1 or more of the following: 1. clinical symptoms consistent with GERD as determined by the investigator 2. a diagnosis of erosive esophagitis by endoscopy 3. esophageal biopsy with histopathology consistent with reflux esophagitis 4. abnormal pHmetry consistent with reflux esophagitis 5. other test result consistent with GERD 4. Written informed consent from the parent or legally authorized representative/guardian and participant assent per local IRB recommendation of ageappropriate consent and assent requirements 1. Use of pantoprazole, lansoprazole, omeprazole, esomeprazole or rabeprazole within 48 hours prior to dose of study drug 2. Use of fluoxetine, fluvoxamine, ketoconazole, ticlopidine, felbamate, topiramate, valproic acid, phenobarbital, carbamazepine, erythromycin, clarithromycin, grapefruit juice, verapamil, diltiazem, cimetidine, St. John's Wort, rifampin, rifapentine within seven days prior to dose of study drug 3. Consumption of food after midnight on the day of the baseline visit 4. Symptomatic asthma 5. Type I diabetes 6. History of adverse reaction to PPI 7. Impaired hepatic activity as defined as any of the following: AST ≥150 IU/L, ALT ≥150 IU/L, total bilirubin ≥2.0 mg/dl, or alkaline phosphatase ≥600 IU/L 8. Serum creatinine ≥2.0 mg/dL 9. For females of childbearing potential, a positive pregnancy test result 10. Known infection with hepatitis B, C, or HIV 11. Any other condition that, in the opinion of the principal investigator, makes participation unadvised or unsafe.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>obese</keyword>
	<keyword>children</keyword>
	<keyword>adolescents</keyword>
	<keyword>GERD</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>